Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial About Treatment of Mild to Moderate Persistent Alergic Rhinnitis With Test or Reference Mometasone (PUMA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Sign and date the informed consent form or, in case of subjects younger than 18 years, the document must also be signed by a legal guardian;~* ≥ 12 years old;~* Suffer from mild to moderated persistent alergic rhinitis;~* Total NIS scale score ≥ 4 points at the screening visit and within at least 4 of the 7 days before the randomization visit;~* Indication for use nasal corticosteroid;~* Present with alergic rhinitis symptoms for at least 2 years;~* May undergo a washout period of at least 2 weeks~Exclusion Criteria:~* Patients with severe alergic rhinitis;~* Patients with severe co-morbidities (at the investigator's criteria);~* Patients with mild to severe persistent asthma;~* Clinical history of infection of the airways 30 days before the study entry;~* Patients with structural changes causing nasal obstruction, such as pronounced nasal septum deviation, nasal polyps or any other type of nasal malformation;~* For female subjects, be pregnant or breastfeeding or planning to become pregnant or unwilling to use safe birth control methods during the study;~* subjects in need of other drugs to treat alergic rhinitis, such as anti-immunoglobulin E, immunotherapy, anti-leukotrienes, oral corticosteroids, inhalant corticosteroids, or any administration route other than cutaneous;~* Active smokers (use of cigarette, pipe, cigar or any other form of tobacco in any amount within the past 3 months before the study entry);~* Participation in another clinical study within the past 12 months;

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mometasone (Type: EXPERIMENTAL): None
- Nasonex® (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).